These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 112422

  • 1. [Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl)].
    Burkert H, Schnitker J, Fichtner E.
    MMW Munch Med Wochenschr; 1979 Jun 01; 121(22):760-2. PubMed ID: 112422
    [Abstract] [Full Text] [Related]

  • 2. Controlled clinical studies with an antidote against the urotoxicity of oxazaphosphorines: preliminary results.
    Scheef W, Klein HO, Brock N, Burkert H, Günther U, Hoefer-Janker H, Mitrenga D, Schnitker J, Voigtmann R.
    Cancer Treat Rep; 1979 Mar 01; 63(3):501-5. PubMed ID: 106965
    [Abstract] [Full Text] [Related]

  • 3. [Uroprotection with mesna in the chemotherapy of malignant tumors with oxazaphosphorines. Biometric evaluation of a sequential clinical study].
    Schnitker J.
    Arzneimittelforschung; 1982 Mar 01; 32(10):1334-8. PubMed ID: 6817761
    [Abstract] [Full Text] [Related]

  • 4. [High-dose ifosfamide therapy: systemic use of a mucolytic agent for the reduction of urotoxicity].
    Marti C, Steiner R, Viollier AF.
    Schweiz Med Wochenschr; 1979 Dec 08; 109(47):1885-7. PubMed ID: 119317
    [Abstract] [Full Text] [Related]

  • 5. [Effects of mesna (2-mercaptoethane sodium sulfonate) in children with malignant disease receiving oxazaphosphorine chemotherapy].
    Iwasaku-Fujimoto M, Fujiwara F, Todo S, Morioka Y, Imashuku S.
    Gan To Kagaku Ryoho; 1990 Mar 08; 17(3 Pt 1):403-6. PubMed ID: 2106836
    [Abstract] [Full Text] [Related]

  • 6. Clinical overview of mesna.
    Burkert H.
    Cancer Treat Rev; 1983 Sep 08; 10 Suppl A():175-81. PubMed ID: 6414692
    [Abstract] [Full Text] [Related]

  • 7. [Clinical evaluation of Mitexan in the prevention of urinary tract complications during treatment with Holoxan].
    Czownicki Z, Utracka-Hutka B.
    Nowotwory; 1981 Sep 08; 30(4):377-83. PubMed ID: 6792599
    [No Abstract] [Full Text] [Related]

  • 8. Treatment of metastatic renal cancer with ifosfamide and mesnum with and without irradiation.
    Fosså SD, Talle K.
    Cancer Treat Rep; 1980 Sep 08; 64(10-11):1103-8. PubMed ID: 6780190
    [Abstract] [Full Text] [Related]

  • 9. Ifosfamide and Mesna in advanced malignancies.
    Li GC, Brock N, Li JQ, Guan ZZ, He YJ.
    Chin Med J (Engl); 1988 Mar 08; 101(3):213-20. PubMed ID: 3136996
    [No Abstract] [Full Text] [Related]

  • 10. Prevention of isophosphamide-induced urothelial toxicity with 2-mercaptoethane sulphonate sodium (mesnum) in patients with advanced carcinoma.
    Bryant BM, Jarman M, Ford HT, Smith IE.
    Lancet; 1980 Sep 27; 2(8196):657-9. PubMed ID: 6106781
    [Abstract] [Full Text] [Related]

  • 11. Acrolein, the causative factor of urotoxic side-effects of cyclophosphamide, ifosfamide, trofosfamide and sufosfamide.
    Brock N, Stekar J, Pohl J, Niemeyer U, Scheffler G.
    Arzneimittelforschung; 1979 Sep 27; 29(4):659-61. PubMed ID: 114192
    [Abstract] [Full Text] [Related]

  • 12. Ifosfamide and mesna.
    Schoenike SE, Dana WJ.
    Clin Pharm; 1990 Mar 27; 9(3):179-91. PubMed ID: 2107997
    [Abstract] [Full Text] [Related]

  • 13. Mesnum as a protector against kidney and bladder toxicity with high-dose ifosfamide treatment.
    Falkson G, Van Dyk JJ, Stapelberg R, Falkson HC.
    Cancer Chemother Pharmacol; 1982 Mar 27; 9(2):81-4. PubMed ID: 6816479
    [Abstract] [Full Text] [Related]

  • 14. The efficacy of mesna (2-mercaptoethane sodium sulfonate) as a uroprotectant in patients with hemorrhagic cystitis receiving further oxazaphosphorine chemotherapy.
    Andriole GL, Sandlund JT, Miser JS, Arasi V, Linehan M, Magrath IT.
    J Clin Oncol; 1987 May 27; 5(5):799-803. PubMed ID: 3106585
    [Abstract] [Full Text] [Related]

  • 15. Detoxification of urotoxic oxazaphosphorines by sulfhydryl compounds.
    Brock N, Pohl J, Stekar J.
    J Cancer Res Clin Oncol; 1981 May 27; 100(3):311-20. PubMed ID: 6792207
    [Abstract] [Full Text] [Related]

  • 16. Cyclophosphamide and ifosfamide: role of uroprotective agents.
    Williams SD, Munshi N, Einhorn LH, Loehrer PJ.
    Cancer Invest; 1990 May 27; 8(2):269. PubMed ID: 2119246
    [No Abstract] [Full Text] [Related]

  • 17. [Antidote against the urotoxic effects of the oxazaphorine derivatives cyclophosphamide, ifosfamide and trofosfamide].
    Brock N, Stekar J, Pohl J.
    Naturwissenschaften; 1979 Jan 27; 66(1):60-1. PubMed ID: 106307
    [No Abstract] [Full Text] [Related]

  • 18. Evaluation of a cooperative clinical study of the cytostatic agent ifosfamide.
    Schnitker J, Brock N, Burkert H, Fichtner E.
    Arzneimittelforschung; 1976 Jan 27; 26(10):1783-92. PubMed ID: 798586
    [Abstract] [Full Text] [Related]

  • 19. Proceedings of a symposium on ifosfamide (Mitoxana; Holoxan) and Mesna (Uromitexan). Coventry, U.K., 16-18 March 1983.
    Cancer Treat Rev; 1983 Sep 27; 10 Suppl A():1-192. PubMed ID: 6414687
    [No Abstract] [Full Text] [Related]

  • 20. Ifosfamide/mesna and hematuria.
    Pratt CB, Goren MP.
    Cancer Treat Rep; 1987 Nov 27; 71(11):1124-5. PubMed ID: 3119210
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.